Remission Rate of Newly Diagnosed Type 2 Diabetes Outpatients Treated With Short-term Intensive Insulin Therapy

• Status: Completed
• Trial end date: 2015-02-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the long-term remission rate of short-term intensive insulin (STII) therapy in newly diagnosed type 2 diabetes outpatients and investigate the predictors contributing to the remission rate.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Qianfoshan Hospital
• Treatments: Insulin; Insulin, Globin Zinc; Metformin; Pioglitazone

Criteria

Inclusion Criteria:

• Newly diagnosed, insulin-naive type 2 diabetes outpatients

• Diabetes duration less than 1 year

Exclusion Criteria:

• Various acute complications

• Hepatic transaminase >2.5x normal reference value (glutamic-pyruvic transminase>100U/L, glutamic-oxalacetic transaminase > 100U/L)

• Abnormal renal functions (serum cretinine>the normal reference value)

• Cardiac insufficiency (America NYHA caediac function >3)

• Type 1 diabetes mellitus

• Ongoing hormone therapy

• Women in gestation and lactation

• Patients with other endocrine disorders